1 Start 2 Complete InstructionsPlease complete the Module 6: Cardiovascular Disease Follow-up Survey and tell us what you learned from this module. Your response is important, and will be used to demonstrate the value of this educational program and to guide development of future CME activities. Thank you for your participation. Please provide your email so we can contact you with promotional information including drawings and prizes for completing this survey. This field is optional. Coronary CT angiography is a useful tool when added to CAC for primary prevention. * True False Which of the following is TRUE about 12-lead EKG assessment? * Has a clear role in risk assessment for primary prevention, Should be used in everyday cardiometabolic practice Most useful in asymptomatic patients for assessing acute coronary injury and arrhythmia Most useful in symptomatic patients for assessing acute coronary injury and arrhythmia In a patient with type 2 diabetes and CAD with low risk of bleeding, which of the following antithrombotic regimens would you favor? * Aspirin alone Clopidogrel alone Aspirin + low dose rivaroxaban A lower ABI (ankle brachial index) indicates a _________ risk for PAD * Lower Higher Intermediate ABI is not associated with risk of PAD A patient presents with suspected MI, and ECG reveals no ST elevation; the patient seems stable. According to the 2020 NSTE-ACS guidelines from the European Society of Cardiology, which of the following would you do next to assess this patient? * Echocardiography High-sensitivity cardiac troponin (hs-cTn) Coronary angiography According to the guidelines, which of the following is first-choice therapy for the prevention of stroke in patients with atrial fibrillation? * Direct oral anticoagulants (DOACs) Aspirin Warfarin Left atrial appendage occlusion Which of the following types of heart failure is more closely associated with cardiometabolic comorbidities? * HFpEF HFrEF HFmrEF HFimpEF The SGLT2 inhibitors have become the 4th foundational therapy recommended for HFrEF. Which of the following constitutes the most convincing reason? * Reduction of symptoms of HF Rapid and profound diuresis Lowering of mortality consistent across all SGLT2 agents Early reduction of HF hospitalizations Which of the following is TRUE about unique aspects of aortic stenosis in women? * Women with aortic stenosis have a smaller annulus compared to men Women with aortic stenosis have more calcification of the aortic valve Women with aortic stenosis are diagnosed earlier than men Women with aortic stenosis have lower incidence of low flow/low gradient aortic stenosis when compared to men How many patient encounters have you had in the last 90 days? * <200 200 400 600 800 1000 1200 >1200 As a result of this educational activity, did you make any changes to your clinical practice? * Yes No What specific changes did you make to your practice as a result of information received in this activity? (Select all that apply) * Optimize guideline-directed therapy for HF regardless of baseline ejection fraction Consider SGLT-2 inhibitors for prevention and treatment of heart failure in patients across the HF spectrum Consider women-specific risk factors when evaluating and treating women with CVD or at CVD risk Recommend non-invasive imaging tests for primary CVD prevention Consider or refer patients for invasive imaging when appropriate Recommend antithrombotic and antiplatelet therapy for patients with PAD or CAD according to current evidence and guidelines Assess and screen cardiometabolic patients with PAD for risk of adverse CV and limb events What additional improvements have you made in your clinical practice after participating in this activity? * What barriers are currently preventing you from making these changes? (select all that apply) * Formulary restrictions Insurance/financial issues Time constraints Lack of interprofessional team support System constraints Treatment related adverse events Patient adherence/compliance None Were the changes that you made in clinical practice beneficial to patient care?* * Yes No Has this course improved the comprehensive treatment of your patients with cardiometabolic disease or cardiometabolic risk? * Yes No Please explain your above answer. * Leave this field blank
